Thailand In Vitro Fertilisation (IVF) Service Market Analysis Sample Report

Thailand IVF
Service Market
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

This report presents a strategic analysis of the Thailand In Vitro
Fertilisation (IVF) Service Market and a forecast for its development
in the medium and long term. It provides a comprehensive overview of the
market value, dynamics, segmentation, types of clinical diagnostics, point-
of-care testing, main players, growth and demand drivers, challenges &
future outlook, etc. This is one of the most comprehensive reports about
the Thailand In Vitro Fertilisation (IVF) Service Market, and offers
unmatched value, accuracy, and expert insights

3
A Sample Report on Thailand In Vitro Fertilisation (IVF) Service Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. In Vitro Fertilisation (IVF) Service Overview 12-25
1.1. Overview
1.2. Thailand Overview
1.3. Economic Overview: Thailand
1.4. In Vitro Fertilisation (IVF) Service Market in Thailand
1.5. Healthcare Services Market in Thailand
1.6. Healthcare Scenario in Thailand
1.7. Health Insurance Coverage: Thailand
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 26-32
2.1 Market size and forecasts (Excel and Methodology)

5
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. By Cycle Type
2.2.2. By Type of Treatment
2.2.3. By Cause of Infertility
2.2.4. By End User
3. Market Dynamics 33-37
3.1. Market Growth Drivers
3.1.1. Thailand In Vitro Fertilisation (IVF) Service Market Driver 1
3.2. Market Restraints
3.2.1. Thailand In Vitro Fertilisation (IVF) Service Market Restraint 1

6
Table of Content
CONTENT PG. NO.
3.2.3. Thailand In Vitro Fertilisation (IVF) Service Market Restraint 2
4. Competitive Landscape 38-48
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Piyavate Hospital
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. First fertility
4.2.2.1. Overview

7
Table of Content
CONTENT PG. NO.
4.2.3. Bumrungrad International Hospital
4.2.3.1. Overview
4.2.4. Samitivej Hospital
4.2.4.1. Overview

8
Table of Content
CONTENT PG. NO.
4.2.5. Bangkok IVF Center
4.2.5.1. Overview
4.2.6. Vejthani Hospital
4.2.6.1. Overview

9
Table of Content
CONTENT PG. NO.
4.2.7. Superior A.R.T.
4.2.7.1. Overview
4.2.8. Siriraj Hospital
4.2.8.1. Overview

10
Table of Content
CONTENT PG. NO.
4.2.9. Vibhavadi Hospital
4.2.9.1. Overview
4.2.10. Pattaya IVF Center
4.2.10.1. Overview

11
Table of Content
CONTENT PG. NO.
5. Reimbursement Scenario 49-56
5.1. Reimbursement Regulation in Thailand
5.2. Reimbursement Process for IVF in Thailand
5.3. Reimbursement Process for IFV Services in Thailand
5.4 Reimbursement Process – Medicare
5.5 Reimbursement Process - Medicaid
6. Methodology & Scope 57-62

Thailand In Vitro Fertilisation (IVF) Service Market Analysis
1. In Vitro Fertilisation (IVF) Service Overview

13
1.1 Overview of In Vitro Fertilisation (IVF) Service in the World
Prevalence of InfertilityGlobally ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
1 in 6
people globally
affected by infertility
2.5% to 12%
male infertility range globally
Over 8 Mn
IVF children have been born
Over 2.5 Mn
cycles are being
performed every year,
resulting in over 500,000
deliveries annually
17.5% of the adult
population affected
by infertility
48 Mn
couples and 186 Mn
individuals worldwide live
17.8%
Lifetime prevalence was in high-
income countries
6.5%
Lifetime prevalence was
in low- and middle-income
countries.

14
1.1 Overview of In Vitro Fertilisation (IVF) Service Market in the World
(continued)
North America
~ Market Size of
$XX Bn
Europe
~Revenue to reach
$XX Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of
$XX Bn
Thailand Market
~$XX Mn Market

15
1.2 Thailand Overview
71.6 Mn
Is the population of
Thailand, in 2021
41
Is the median age
in Thailand, in 2022
50^ Bn
Is the Gross
Domestic Product
(GDP) in Thailand in
2021
$7,066.19
per capita was the
amount of national
health expenditures in
2021
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

16
1.3 Economic Overview: Thailand
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Thailand, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Thailand, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Overview of In Vitro Fertilisation (IVF) Service in Thailand
Success rate of IVF service in Thailand
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Thailand
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
99%
IVF with Donor Egg
75%
Self IVF Program
50%
IVF with medical
conditions
85%
IVF with PGD/PGT
90%
IVF with ICSI
82%
Laser assisted
hatching program
▪ The current fertility rate for Thailand in 2023 is 1.461 births per woman, a
1.02% decline from 2022.
▪ The fertility rate for Thailand in 2022 was 1.476 births per woman, a 1.01%
decline from 2021.
decline from 2020.
decline from 2019.

18
1.5 Healthcare Services in Thailand
xx xx xx xx xx xx xx xx xx
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Thailand Pharmaceutical Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Healthcare Services market in Thailand, which includes the market size, current
trends and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

19
1.6 Healthcare Scenario in Thailand
Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research
to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
This is the budget of the US govt. for public insurance, you will get Thailand govt. for public insurance in Final Report
Illustrative

20
1.6 Healthcare Scenario: IVF Patient Journey
The patient begins by scheduling
an initial consultation with a fertility
specialist or reproductive
endocrinologist at a reputable IVF
clinic in Thailand. During this
consultation, the doctor will review
the patient's medical history,
perform necessary examinations,
and discuss potential treatment
options.
Based on the fertility
assessment results and the
patient's individual
circumstances, the doctor will
develop a personalized
treatment plan. This plan may
include medication protocols,
stimulation protocols, and the
recommended number of IVF
cycles.
The patient begins ovarian
stimulation, which involves
taking fertility medications to
stimulate the ovaries and
promote the growth of multiple
follicles. Regular monitoring
through ultrasound scans and
blood tests is conducted to
assess follicular development.
The patient undergoes a series of
fertility assessments, including blood
tests, hormonal evaluations, and
ultrasound scans. These tests help
the doctor assess the patient's ovarian
reserve, hormone levels, and overall
reproductive health.
Ovarian Stimulation
Treatment Planning
Once the follicles reach the
appropriate size, the patient
undergoes an egg retrieval
procedure. This is typically
performed under sedation or
anesthesia, and a needle is used
to retrieve the mature eggs from
the ovaries.
After a few days of
development, the embryos are
transferred into the uterus. The
number of embryos transferred
is determined based on factors
such as the patient's age,
embryo quality, and the doctor's
recommendation.
Following the embryo transfer,
the patient may receive luteal
phase support in the form of
hormone medications to assist
with implantation and support
early pregnancy.
The retrieved eggs are then fertilized
with sperm in the laboratory through
either conventional IVF or
Intracytoplasmic Sperm Injection
(ICSI) technique. The embryos are
closely monitored for development.
Luteal Phase Support
Embryo Transfer
Fertility Assessment
Fertilization
Approximately two weeks after
the embryo transfer, a
pregnancy test is conducted to
determine if the treatment was
successful. If the test is positive,
the patient will continue with
regular follow-up appointments
and monitoring to ensure a
healthy pregnancy.
Pregnancy Test
Initial Consultation
Egg Retrieval:

21
1.7 Health Insurance Coverage
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar
year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by
Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
This is the US Health Insurance coverage, you will get Thailand Health Insurance coverage in Final Report
Illustrative

22
1.8 Budget of Thailand Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Medicaid $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Medicaid 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

23
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

24
1.9 In Vitro Fertilization Market News (continued)
Company Name
Amount /
Duration
Year Key Pointers
- June 2022
▪ Oma Fertility emerges from stealth and introduces a first-of-its-kind
network of fertility clinics, offering families science-forward, AI-informed
fertility treatments, paving the way for a new standard in IVF success
rates.
- January 2022
▪ Boston IVF, one of the world’s most experienced fertility providers, signed
a partnership with the Delaware Institute for Reproductive Medicine
(DIRM). The unique partnership aims to deliver world-class fertility
treatments and care locally through innovative treatments like in vitro
fertilization (IVF), preimplantation genetic testing, male infertility, and
others.
Latest Deals In Thailand

25
1.9 In Vitro Fertilization Market News (continued)
Latest Deals In Thailand
Company Name
Amount /
Duration
Year Key Pointers
-
-
Illustrative

2. Market Size and Forecasting

27
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Thailand IVF Market Forecast, 2022-2030 (in $Bn)
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
and other details related to the topic
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Thailand Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Thailand Market Size (Bn
$)
61 74 84 87 91 95 99 106
Illustrative

28
2.2 Snapshot of IVF Service Market Segmentation
By Type of Treatment: By Cause of Infertility: By End User
Fresh In Vitro
Fertilization Cycles
Thawed In Vitro
Donor Egg In Vitro
Conventional IVF
▪ In this section you will get an understanding of the segmentations which will cover the Thailand IVF Service Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
By Cycle Type:
ICSI
FET
Fertility Clinics
Hospitals
Surgical Centers
Donor egg or sperm
IVF
PGT
Female factor
infertility
Male factor infertility
Unexplained
infertility
Natural cycle IVF.
Clinical Research
and Institute

29
Thailand Cancer Market Share, By Cycle Type (2022)
Fresh In Vitro
Fertilization
Cycles
Thawed In Vitro
Fertilization
Cycles
Donor Egg In
Vitro Fertilization
Cycles
▪ Fresh In Vitro Fertilization Cycles
market in Thailand is a significant
component of the overall IVF Service
treatment market
▪ It has the maximum market share in
Thailand cancer market with
approximately xx%
2.2.1 Market Segmentation: By Cycle Type
Illustrative

30
Conventional IVF
ICSI
FET
Donor egg or
sperm IVF
PGT
Natural cycle
IVF.
2.2.2 Market Segmentation: By Type of Treatment
▪ By Type of treatment market in
Thailand, conventional IVF is a
significant component of the overall IVF
service market
final report
Thailand Cancer Market Share, By Type of Treatment (2022)
Illustrative

31
Thailand Cancer Market Share, By Cause of Infertility (2022)
Female factor
infertility
Male factor
infertility
Unexplained
infertility
2.2.3 Market Segmentation: By Cause of Infertility
▪ Female factor infertility have the
maximum market share in Thailand IVF
service market with approximately xx%
final report
Illustrative

32
UAE Nutritional Supplements Market Share, By End User (2022)
Fertility Clinics
Hospitals
Surgical Centers
Clinical
Research and
Institute
2.2.4 Market Segmentation: By End User
▪ Fertility clinics have the maximum
market share in Thailand IVF service
market with approximately xx%
final report
Illustrative

3. Market Dynamics

34
3.1 Market growth drivers
▪ Incidence of cancer is increasing in Thailand, with more than 1.8 Mn new
cancer cases expected to be diagnosed in 2023
▪ This is driving the demand for cancer treatments and creating
opportunities for growth in the cancer market
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.1 Incidence of cancer is increasing in Thailand, with more than 1.8 Mn new cancer cases expected to be
diagnosed in 2023
Incidence of Cancer in Thailand
Illustrative
These are the drivers and restraints of US cancer market you will get Thailand IVF services market drivers in Final Report

35
3.1 Market growth drivers (continued)
Top countries that are leveraging
technology in their fight against cancer
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
3.1.2 Death rate from cancer in Thailand has declined by 31% from 1992 to 2022, largely due to advances in
technology and treatment options
▪ Thailand has a long history of investing in cancer research
and treatment, and as a result, has become a world leader in
the field
▪ IT has a robust healthcare infrastructure, including world-
renowned research institutions, hospitals, and clinics, that
are dedicated to cancer treatment and research
▪ One of the key factors that has allowed Thailand to stay
ahead in the field of cancer research and treatment is the
high level of investment in cancer-related research
Illustrative

36
3.1 Market growth drivers (continued)
Fundings from government and other
organizations
3.1.3 In 2021, the National Cancer Institute (NCI) received $6.4 Bn in funding from Thailand federal government to
support cancer research and training programs
▪ Thailand government provides significant support and
funding for cancer research and treatment, which is driving
innovation and growth in the cancer market
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
Source Year Fund ($)
National Cancer
Institute (NCI)
2021 $ 6.4 Bn
Centers for Disease
Control and
Prevention (CDC)
2021 $ 501 Mn
American Cancer
Society (ACS)
2020 $ 150 Mn
Susan G. Komen 2020 $ 98 Mn
Illustrative

37
3.2 Market restraints
3.2.1 In 2020, the
average cost of a new
cancer drug was over
$150,000 per year
▪ Cancer treatments can be very
expensive and can lead to financial
burden for patients and healthcare
systems
▪ Cost of cancer treatment varies
depending on the type of cancer,
stage of cancer, and treatment
options
▪ Some common cancer treatments,
such as chemotherapy and
radiation therapy, can cost tens of
thousands of dollars
3.2.2 Average cost of
developing a new cancer
drug that is ultimately
approved by the FDA is over
$2.6 Bn
▪ Regulatory requirements for cancer
treatments can be very stringent,
which can slow down the approval
process and limit access to new
treatments
▪ This can be a lengthy and costly
process, which can delay the
availability of new treatments for
patients
3.2.3 Demand for cancer care is
expected to increase by 42% by
2025, while the supply of
oncologists is only expected to
increase by 28%
▪ There is a shortage of oncologists
in Thailand, which can limit access
to cancer treatments and create
barriers to growth in the cancer
market
▪ Oncologists are physicians who
specialize in the diagnosis and
treatment of cancer
▪ However, the supply of oncologists
is not keeping pace with the
demand
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative

4. Competitive Landscape

39
4.1 Major Market Share
▪ Thailand IVF service market is a highly
competitive space, with many companies
developing and marketing cancer
treatments
▪ Some of the top companies in Thailand IVF
service market based on revenue and
market share include
interest
Revenue of Major players in Thailand IVF Service Market ($ Mn)
XX
Company10
Company 1
Company 2
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Illustrative

40
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Piyavate Hospital
3
Bumrungrad International
Hospital
5 Bangkok IVF Center
7 Superior A.R.T.
9 Vibhavadi Hospital
2 First fertility
4 Samitivej Hospital
6 Vejthani Hospital
8 Siriraj Hospital
Pattaya IVF Center
10
Key Note:
Illustrative

41
4.2.1 Piyavate Hospital
Founded in: 1993
HQ: Bangkok, Thailand
Type: Private
Revenue: $73.2 Mn
Website:. https://piyavate.com/
▪ Piyavate Hospital offers a wide range of medical specialties and
services
▪ These include general medicine, surgery, obstetrics and
gynecology, pediatrics, orthopedics, cardiology, dermatology,
neurology, urology, ophthalmology, and more
▪ They also provide specialized services such as fertility treatments,
including IVF (In Vitro Fertilization) and IUI (Intrauterine
Insemination)
Key Executives
➢ Dr. Witit Attavejkul: Managing
Director and CEO
➢ Dr. Chareoung Chandrakamol:
President
➢ Paisarn Nitiprapa: Chief Financial
Officer (CFO)
➢ Benjamin Tan: Assistant to CEO
and Director Of Marketing
IVF (In Vitro Fertilization) Donor Egg IVF
ICSI (Intracytoplasmic Sperm
Injection):
Surrogacy
Blastocyst Culture and
Transfer
Fertility preservation
Frozen Embryo Transfer (FET)
Preimplantation Genetic
Testing (PGT)
IVF services provided by Piyavate Hospital Recent Activity / Press Coverage
▪ September 21, 2022: Creativity Award is presented to hospitals that
demonstrate ongoing creativity and innovative approaches in various ways
to maximize benefits for their customers. Which recognizes hospitals that
maintain excellent service standards
▪ 2022: Piyavate Hospital has made significant strides in improving the
pregnancy success rate among its clients. In 2022, they achieved an
impressive overall success rate of 63.96%
▪ Notably, clients aged under 29 years experienced an exceptional success
rate of 85.71%, while those in the 30-39 age group achieved a success
rate of 65.6%. For clients aged between 40-49 years, the success rate
stood at 48.65%

42
4.2.1 Piyavate Hospital (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Piyavate Hospital and
PTT-CP Group
Collabration -
August,
2021
▪ Piyavate Hospital’ joins hands with ‘PTT-CP Group’ to open a
350-bed field hospital to support mid- to critical covid patients
Latest Deals - Mergers and Acquisitions
Illustrative

43
XX
XX XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
4.2.1 Piyavate Hospital (continued)
Revenues ($Bn), 2020-2030
▪ According to Piyavate Hospital 2020
financial report, the hospital had total
revenue of XX Mn in 2022
▪ Hospital’s IVF service division generated of
XX Mn in 2022.
▪ Revenue generated by Piyavate Hospital in
2022 reflects the hospital’s continued
growth and success in the healthcare
industry
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

44
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

45
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

46
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

47
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

49
5.1 Reimbursement Regulation in Thailand
In Thailand, the healthcare system consists of both public and private sectors. The
reimbursement regulations in Thailand depends on whether the services are provided
through the public universal healthcare scheme or private health insurance. Here are some
key aspects of healthcare reimbursement regulations in Thailand:
▪ Public Universal Healthcare Scheme (UC Scheme):
o Under the UC Scheme, which is known as the "30-Baht Scheme," Thai citizens
are eligible for basic healthcare services at public healthcare facilities. The
reimbursement is primarily handled by the National Health Security Office
(NHSO). Patients are required to pay a nominal fee of 30 Baht per visit, and the
rest of the costs are reimbursed by the scheme
▪ Social Security Scheme:
o Employees and workers in the formal sector contribute to the Social Security
Scheme, which provides health insurance coverage. Reimbursement for
healthcare services is managed by the Social Security Office (SSO). The scheme
covers both inpatient and outpatient services
▪ Civil Servant Medical Benefit Scheme:
o Civil servants and their dependents are covered under the Civil Servant Medical
Benefit Scheme. The reimbursement for healthcare services is administered by
the Comptroller General's Department (CGD). The scheme provides coverage for
both inpatient and outpatient services, with specific reimbursement rates based
on the type of service
Public and Private health insurance
coverage in Thailand
Public
Insurance
36%
Private
Health
Insurance
45%
Uninsured
19%
Health Insurance Coverage, 2022

50
5.1 Reimbursement Regulation (continued)
▪ Private Health Insurance:
o Private health insurance plays a significant role in Thailand's healthcare system. The reimbursement regulations for private
health insurance plans may vary depending on the specific insurance provider and policy. Private insurers typically have their
own coverage limits, reimbursement rates, and eligibility criteria
▪ Uninsured Population:
o Despite efforts to achieve universal health coverage, there is still a portion of the Thai population that remains uninsured.
This include individuals who are not eligible for public health insurance schemes or have not obtained private health
insurance coverage

51
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care
38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative
This is the reimbursement regulation of of the US govt. for public insurance, you will get Thailand reimbursement regulations in Final Report

52
5.2 Reimbursement Process for IVF in Thailand
The reimbursement process for IVF (In Vitro Fertilization) in Thailand can vary depending on the specific healthcare scheme or insurance
coverage. Here is a general overview of the reimbursement process for IVF in Thailand:
▪ Public Health Insurance Schemes:
o Under the public health insurance schemes in Thailand, such as the Universal Coverage Scheme (UC Scheme) or the Social
Security Scheme, coverage for IVF may be provided to eligible individuals. However, the specific reimbursement process, eligibility
criteria, and coverage limits may vary. It is advisable to contact the respective healthcare authority or insurer managing the specific
scheme for detailed information on the reimbursement process for IVF.
▪ Private Health Insurance:
o For individuals with private health insurance coverage, the reimbursement process for IVF will depend on the terms and conditions
of the insurance policy. Some private health insurance plans may offer coverage for IVF treatment, while others may have
exclusions or limitations. It is essential to review the policy details and contact the insurance provider directly to understand the
reimbursement process, required documentation, coverage limits, and any pre-authorization requirements.
▪ Out-of-Pocket Payment:
o In cases where IVF treatment is not covered by health insurance or the patient does not have insurance coverage, individuals may
need to pay for the treatment out of pocket. The healthcare provider will typically provide a detailed breakdown of the costs involved,
including consultation fees, medication, laboratory tests, and the IVF procedure itself.

53
5.3 Reimbursement Process for IFV Services in Thailand
The reimbursement process in the US healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

54
5.4 Reimbursement Process - Medicare
Medicare
Population Covered
▪ 100% population is covered under this scheme
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an
individuals Medicare account
Provider Restrictions/
Selection
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

55
5.5 Reimbursement Process - Medicaid
Medicaid
Population Covered
▪ 38% population is covered under this scheme
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease
Provider Restrictions/
Selection
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Healthcare Services
and healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Healthcare Services
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Thailand In Vitro Fertilisation (IVF) Service Market Analysis Sample Report

Recommended

Recommended

More Related Content

Similar to Thailand In Vitro Fertilisation (IVF) Service Market Analysis Sample Report

Similar to Thailand In Vitro Fertilisation (IVF) Service Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Thailand In Vitro Fertilisation (IVF) Service Market Analysis Sample Report